going gray semaglutide Semaglutide: The benefits and risks of the weight-loss wonder drug sweeping America GLP-1 drug use nearly quadruples

Contact your GP if you experience severe or persistent abdominal pain, persistent vomiting, signs of dehydration, blood in vomit or stools, severe heartburn unresponsive to antacids, or if you require daily antacid use for more than two weeks

Medicines with a narrow therapeutic index where small changes in blood concentration can have significant clinical consequences merit particular attention

Air bubbles take up space in the syringe barrel, displacing medication

2 Pathogenesis and spectrum of MAFLD

In clinical trials of semaglutide injection for weight management, cholelithiasis was reported in 1.6% of semaglutide-treated patients compared with 0.7% of placebo-treated patients

Missing injections or stopping treatment because of side effects may interrupt progress and contribute to disappointing results